Source: Incysus Therapeutics, Inc

Incysus Therapeutics’ Scientific Co-Founder Lawrence Lamb, Ph.D. and Marcela Maus, M.D., Ph.D. to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting

Symposium Title: “Tipping Point: Gene Therapy Entering the Market”

Bruce Levine, Ph.D. to Present: “Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to Industry”

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Lawrence S. Lamb, Ph.D., Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus, and Marcela V. Maus, M.D., Ph.D., Director of Cellular Immunotherapy at the Massachusetts General Hospital Cancer Center in Boston, and a founding member of the Incysus Scientific Advisory Board (SAB), will co-chair a scientific symposium during the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), in Chicago, Illinois. 

The symposium, titled, “Tipping Point: Gene Therapy Entering the Market” has been organized by the Clinical Trials and Regulatory Affairs Committee of ASGCT and will include Bruce L. Levine, Ph.D. the Barbara and Edward Netter Professor in Cancer Gene Therapy, and Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine at the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania.  Dr. Levine is also a founding member of Incysus’ SAB and his presentation is titled, “Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to Industry.”

   Scientific Symposium 300 
 Tipping Point: Gene Therapy Entering the Market
    Date and Time:  Friday, May 18, 2018, 8:00 a.m. CT
   Co-Chairs: Lawrence S. Lamb, Ph.D., Marcela V. Maus, M.D., Ph.D.
   Speaker: Bruce L. Levine, Ph.D.
   Presentation: Regulatory and Technical Lessons Learned in Transfer of Gene Therapy Products from Academia to Industry

About Incysus Therapeutics, Inc.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. For more information, visit

Incysus Therapeutics, Inc.
(646) 820-8474